Update on the rational use of 90Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 199-208

  Lehnert, Martina ^a   Ludwig, Heinz ^a   Zojer, Niklas ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

90Y ibritumomab tiuxetan; Follicular lymphoma

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ASTHENIA; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CHILL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE; LYMPHOMA CELL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

EID: 77953373764     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Hornig SJ, Rosenberg SA. The natural history of and treatment for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20:75-88. (Pubitemid 23319044)
2. Swenson WT, Woolridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019-5026. (Pubitemid 46224008)
3. Marcus R, Imrie K, Blech A, et al. CVP chemptherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423. (Pubitemid 40223656)
4. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732. (Pubitemid 41742196)
5. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolonges survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol. 2007;25:1986-1992. (Pubitemid 46972781)
6. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824-4831.
7. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104:1258-1265. (Pubitemid 39166497)
8. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem stell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective randomized trial of the German low-grade lymphoma study group. Blood. 2004;104:2667-2674. (Pubitemid 39434946)
9. Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem stell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German low-grade lymphoma study group. J Clin Oncol. 2004;22:4926-4933. (Pubitemid 46638617)
10. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
11. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmuntherapy in patiens with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
12. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
13. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463. (Pubitemid 34525730)
14. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
15. Wiseman GA, Gordon Li, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99:4336-4342. (Pubitemid 34627198)
16. 90Y ibritumomab iuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res. 2005;11:7146-7150.
17. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470. (Pubitemid 26100047)
18. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy. Blood. 2009 Jan 30. [Epub ahead of print].
19. Gopal AK, Press OW, Wilbur SM, et al. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112:830-835.
20. Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113:1412-1421.
21. Witzig TE, White CA, Wiseman GA, et al. Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270. (Pubitemid 46606402)
22. Czuczman M, Emmanouilides C, Darif M, et al.Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285-4292. (Pubitemid 47548569)
23. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
24. Jankowitz R, Joyce J, Jacobs S, et al. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma. Clin Nucl Med. 2008;33:94-96.
25. Gordon LI, Molina A, Witzig TE, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-4431. (Pubitemid 38745967)
26. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)
27. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:629-636. (Pubitemid 43753373)
28. 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008;14:7088-7094.
29. 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. Proc Am Soc Clin Oncol. 2005;23(Suppl 16). Abstract 6577.
30. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II nonrandomised trial (FLUMIZ). Lancet Oncol. 2008;9:352-358.
31. Morschhauser F, Radford J, van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156-5164.
32. 90Y) ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood. 2004; (ASH Annual Meeting)104: Abstract 2633.
33. 90Y ibritumomab tiuxetan as initial treatment for follicular lymphoma (ZEUS Protocol). An Italian Cooperative Study Group. Blood. 2008; (ASH Annual Meeting)112: Abstract 3061.
34. 90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II Study. Blood. 2007; (ASH Annual Meeting Abstracts)110:22.
35. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of highdose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896-2902. (Pubitemid 41510771)
36. Krishnan A, Nademanee A, Fung H, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:90-95.
37. Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2009 Mar 2. [Epub ahead of print].
38. Devizzi L, Guidetti A, Tarella C, et al. High-dose yttrium-90- ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol. 2008;26:5175-5182.
39. 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol. 2007;139:590-599.
40. Bethge WA, Lange T, von Harsdorf S, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced indolent non-Hodgkin lymphoma: interim analysis of a phase II study. Blood. 2008; (ASH Annual Meeting)112:Abstract 1959.
41. Shimoni A, Zwas ST, Oksman Y, et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008;41:355-361. (Pubitemid 351330730)
42. Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun. 2009;30(1):5-15. Review.
43. Hochster H, Weller E, Gascoyne RD, et al. Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. J Clin Oncol. 2009 Mar 2. [Epub ahead of print].
44. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008. (Pubitemid 44920177)
45. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301. (Pubitemid 44794222)
46. McLaughlin P, Neelapu S, Fanale M, et al. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma. Blood. 2009; (ASH Annual Meeting)112: Abstract 3056.
47. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3885-3890.
48. Morschhauser F, Bischof-Delaloye A, Rohatiner AZS, et al. Extended follow-up of the international randomized phase 3 First-Line Indolent Trial (FIT) shows durable benefit of 90 Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma. Blood. 2008; (ASH Annual Meeting)112:Abstract 2002.
49. Gyan E, Foussard C, Bertrand P, et al. Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS). High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113:995-1001.
50. Ladetto M, De Marco F, Benedetti F, et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004-4013.
51. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006;108:2540-2544. (Pubitemid 44776986)
52. Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007;22:684-691. (Pubitemid 350059005)
53. Shah J, Wang W, Harrough VD, et al. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2007;48:1736-1744. (Pubitemid 47386709)
54. 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer. Res. 2005;11:7146s-7150s.
55. Hohloch K, Zinzani PL, Linkesch W, et al. Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network. Blood. 2008; (ASH Annual Meeting)112: Abstact 3064.
56. Vose JM, Bierman PJ, Loberiza FR Jr, et al. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non- Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma. 2007;48:683-690.